Blood S-adenosylmethionine concentrations and lymphocyte methylenetetrahydrofolate reductase activity in diabetes mellitus and diabetic nephropathy

Metabolism: Clinical and Experimental

Volumn 50, Issue 9, 2001, Pages 1014-1018

  Poirier, Lionel A ^a,b,c   Brown, Aliza T ^a,b,c   Fink, Louis M ^a,b,c   Wise, Carolyn K ^a,b,c   Randolph, Carol J ^a,b,c   Delongchamp, Robert R ^a,b,c   Fonseca, Vivian A ^a,b,c  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^c TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CREATININE; HOMOCYSTEINE; S ADENOSYLHOMOCYSTEINE; S ADENOSYLMETHIONINE;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; ENZYME ACTIVITY; ERYTHROCYTE LEVEL; FEMALE; HEMODIALYSIS PATIENT; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; LYMPHOCYTE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PRIORITY JOURNAL; PROTEINURIA; STATISTICAL ANALYSIS;

EID: 0034789257     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1053/meta.2001.25655     Document Type: Article

References (49)

1. S-adenosylmethionine and methylation
2. Phosphatidylcholine as a precursor of choline for acetylcholine synthesis
3. Biochemistry and pharmacology of S-adenosyl-L-methionine and rationale for its use in liver disease
4. Methyl groups in carcinogenesis: Effects on DNA methylation and gene expression
5. Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation and carcinogenesis
6. Biological effects of inhibitors of S-adenosylhomocysteine hydrolase
7. Methyl group deficiency in hepatocarcinogenesis
8. Hepatocyte-like cells within the pancreas of rats fed methyl-deficient diets
9. Folate, vitamin B12, and neuropsychiatric disorders
10. Homocysteine and cardiovascular disease
11. Elevated plasma total homocysteine and C677T mutation of the methylenetetrahydrofolate reductase gene in patients with spina bifida
12. Central and peripheral nervous system pathology of homocystinuria due to 5, 10-methylenetetrahydrofolate reductase deficiency
13. Hyperhomocysteinemia following a methionine load in patients with non-insulin-dependent diabetes mellitus and macrovascular disease
14. Increased levels of plasma homocysteine are associated with nephropathy, but not severe retinopathy in type 1 diabetes mellitus
15. Plasma homocysteine concentrations in Japanese patients with non-insulin-dependent diabetes mellitus: Effect of parenteral methylcobalamin treatment
16. Rapid high performance liquid chromatography assay for total homocysteine levels in human serum
17. Homocystinuria associated with decreased methylenetetrahydrofolate reductase activity
18. Measuring S-adenosylmethionine in whole blood, red blood cells and cultured cells using a fast preparation method and high-performance liquid chromatography
19. Butylated hydroxytoluene modulates DNA methylation in rats
20. Stability of erythrocyte folate
21. Feedback inhibition of methylene-tetrahydrofolate reductase in rat liver by S-adenosylmethionine
22. The role of vitamin B12 and folate in carcinogenesis
23. Association of demyelination with deficiency of cerebrospinal-fluid S-adenosylmethionine in inborn errors of methyl-transfer pathway
24. Effect of betaine on S-adenosylmethionine levels in the cerebrospinal fluid in a patient with methylenetetrahydrofolate reductase deficiency and peripheral neuropathy
25. The pathogenesis of homocysteinemia: Interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine
26. Modulation of methylenetetrahydrofolate reductase activity by S-adenosylmethionine and by dihydrofolate and its polyglutamate analogues
27. Genomic DNA hypomethylation, a characteristic of most cancers, is present in peripheral leukocytes of individuals who are homozygous for the C677T polymorphism in the methylenetetrahydrofolate gene
28. The significance of serum homocysteine levels in diabetic patients on haemodialysis
29. Total homocysteine in patients with type 1 diabetes
30. Impaired glucose tolerance (IGT) is not associated with disturbed homocysteine metabolism
31. Evidence for disturbed S-adenosylmethionine: S-adenosylhomocysteine ratio in patients with end-stage renal failure: A case for disturbed methylation reactions?
32. Metabolic consequences of folate-induced reduction of hyperhomocysteinemia in uremia
33. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects
34. Effects of streptozotocin-induced diabetes and of insulin treatment on homocysteine metabolism in the rat
35. Effects of a high fat sucrose diet on enzymes of homocysteine metabolism in the rat
36. The effect of glucose and insulin on enzymes in homocysteine metabolism
37. Pancreas acinar cell differentiation. VI. Effects of methyl donors and homocysteine
38. 3) methionine
39. Ethionine carcinogenesis
40. Folate deficiency inhibits pancreatic amylase secretion in rats
41. Phosphatidylethanolamine methyltransferase activity in developing, demyelinating, and diabetic mouse brain
42. Sarcolemmal phosphatidylethanolamine N-methylation in diabetic cardiomyopathy
43. Disturbance of methyl group metabolism in alloxan-diabetic sheep
44. Evidence for altered methionine methyl-group utilization in the diabetic rat’s brain
45. Poor metabolic control, early age at onset, and marginal folate deficiency are associated with increasing levels of plasma homocysteine in insulin-dependent diabetes mellitus. A five-year follow-up study
46. Methotrexate hepatotoxicity in psoriatics: Report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up
47. Treatment with low dose methotrexate in rheumatoid arthritis: Risk factors for severe complications
48. Controlled comparison of L-5-methyltetrahydrofolate versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients